tetano
Editor, Senior Moderator
Epidemiol Infect. 2015 Sep 14:1-5. [Epub ahead of print]
[h=1]Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic.[/h] Hardelid P[SUP]1[/SUP], Rait G[SUP]2[/SUP], Gilbert R[SUP]1[/SUP], Petersen I[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We determined prescribing rates of neuraminidase inhibitors (NIs) for influenza in UK primary care since 2009 in relation to national prescribing guidelines. All NI prescriptions issued during the influenza seasons between October 2010 and May 2013 were extracted from The Health Improvement Network (THIN), a large UK primary-care database. We calculated NI prescribing rates per 100 000 person-weeks (pw) by age group, sex, deprivation level, influenza season and presence of chronic conditions with 95% confidence intervals (CIs), and used negative binomial regression models to determine the independent association between these variables and NI prescribing. NI prescribing was rare. The prescribing rate was 1?7/100 000 pw (95% CI 1?7-1?8) during influenza-active periods, and 0?1/100 000 (95% CI 0?1-0?1) during non-active periods. Prescribing rates were highest in 25- to 44-year-olds in 2010/2011 and in persons aged ⩾85 years in 2011/2012 and 2012/2013. Individuals with chronic conditions had significantly higher prescribing rates than persons without (rate ratio 2?62, 95% CI 2?27-3?03). GPs are more likely to prescribe NIs to high-risk individuals and during influenza active periods, as per national guidelines. We could not assess the proportion of patients with influenza-like illness who were prescribed an NI.
[h=4]KEYWORDS:[/h] Antimicrobial drugs; Influenza
PMID: 26364671 [PubMed - as supplied by publisher]
[h=1]Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic.[/h] Hardelid P[SUP]1[/SUP], Rait G[SUP]2[/SUP], Gilbert R[SUP]1[/SUP], Petersen I[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We determined prescribing rates of neuraminidase inhibitors (NIs) for influenza in UK primary care since 2009 in relation to national prescribing guidelines. All NI prescriptions issued during the influenza seasons between October 2010 and May 2013 were extracted from The Health Improvement Network (THIN), a large UK primary-care database. We calculated NI prescribing rates per 100 000 person-weeks (pw) by age group, sex, deprivation level, influenza season and presence of chronic conditions with 95% confidence intervals (CIs), and used negative binomial regression models to determine the independent association between these variables and NI prescribing. NI prescribing was rare. The prescribing rate was 1?7/100 000 pw (95% CI 1?7-1?8) during influenza-active periods, and 0?1/100 000 (95% CI 0?1-0?1) during non-active periods. Prescribing rates were highest in 25- to 44-year-olds in 2010/2011 and in persons aged ⩾85 years in 2011/2012 and 2012/2013. Individuals with chronic conditions had significantly higher prescribing rates than persons without (rate ratio 2?62, 95% CI 2?27-3?03). GPs are more likely to prescribe NIs to high-risk individuals and during influenza active periods, as per national guidelines. We could not assess the proportion of patients with influenza-like illness who were prescribed an NI.
[h=4]KEYWORDS:[/h] Antimicrobial drugs; Influenza
PMID: 26364671 [PubMed - as supplied by publisher]